Patent classifications
C07D239/30
PROCESS FOR THE PREPARATION OF FLUOXASTROBIN AND INTERMEDIATES THEREOF
The invention provides an improved process for the preparation of fluoxastrobin and intermediates thereof. The present invention provides a process for the preparation of fluoaxastrobin, 4,6-dichloro-5-fluoro-pyrimidine and diethyl 2-chloromalonate that are substantially free of unwanted impurities.
PROCESS FOR THE PREPARATION OF FLUOXASTROBIN AND INTERMEDIATES THEREOF
The invention provides an improved process for the preparation of fluoxastrobin and intermediates thereof. The present invention provides a process for the preparation of fluoaxastrobin, 4,6-dichloro-5-fluoro-pyrimidine and diethyl 2-chloromalonate that are substantially free of unwanted impurities.
PTEFB inhibiting macrocyclic compounds
The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
PTEFB inhibiting macrocyclic compounds
The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF
- Ae Nim Pae ,
- Yun Kyung Kim ,
- Sang Min LIM ,
- Sungsu LIM ,
- Jihye SEONG ,
- Jae Wook Lee ,
- Ji Yeon Song ,
- Seulgi SHIN ,
- Hyean Jeong JEONG ,
- Woo Seung SON ,
- Haeun LEE ,
- Da Mi LIM ,
- Seok Kyu KIM ,
- Jee Yun AHN ,
- Chae Won KIM ,
- Ashwini Machhindra LONDHE ,
- Lizaveta GOTINA ,
- Hyojin KIM ,
- Hye Yeon LEE ,
- Nam Gyung KIM ,
- Eunji CHA ,
- Kunhee KIM ,
- Ji Woong LIM
The present invention relates to novel hydrazone derivatives in which a terminal amine group is substituted with an aryl group or a heteroaryl group, and uses thereof.
NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF
- Ae Nim Pae ,
- Yun Kyung Kim ,
- Sang Min LIM ,
- Sungsu LIM ,
- Jihye SEONG ,
- Jae Wook Lee ,
- Ji Yeon Song ,
- Seulgi SHIN ,
- Hyean Jeong JEONG ,
- Woo Seung SON ,
- Haeun LEE ,
- Da Mi LIM ,
- Seok Kyu KIM ,
- Jee Yun AHN ,
- Chae Won KIM ,
- Ashwini Machhindra LONDHE ,
- Lizaveta GOTINA ,
- Hyojin KIM ,
- Hye Yeon LEE ,
- Nam Gyung KIM ,
- Eunji CHA ,
- Kunhee KIM ,
- Ji Woong LIM
The present invention relates to novel hydrazone derivatives in which a terminal amine group is substituted with an aryl group or a heteroaryl group, and uses thereof.
OPIOID RECEPTOR MODULATORS
Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.
P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS
Disclosed herein are p38α mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and therapeutic methods of using the p38α mitogen-activated protein kinase inhibitors.
P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS
Disclosed herein are p38α mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and therapeutic methods of using the p38α mitogen-activated protein kinase inhibitors.
BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.